Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide

A fully synthetic MUC1‐based cancer vaccine was designed and chemically synthesized containing an endogenous helper T‐epitope (MHC class II epitope). The vaccine elicited robust IgG titers that could neutralize cancer cells by antibody‐dependent cell‐mediated cytotoxicity (ADCC). It also activated cytotoxic T‐lymphocytes. Collectively, the immunological data demonstrate engagement of helper T‐cells in immune activation. A synthetic methodology was developed for a penta‐glycosylated MUC1 glycopeptide, and antisera of mice immunized by the new vaccine recognized such a structure. Previously reported fully synthetic MUC1‐based cancer vaccines that elicited potent immune responses employed exogenous helper T‐epitopes derived from microbes. It is the expectation that the use of the newly identified endogenous helper T‐epitope will be more attractive, because it will activate cognate CD4+ T‐cells that will provide critical tumor‐specific help intratumorally during the effector stage of tumor rejection and will aid in the generation of sustained immunological memory.

[1]  S. Cascio,et al.  Intra- and Extra-Cellular Events Related to Altered Glycosylation of MUC1 Promote Chronic Inflammation, Tumor Progression, Invasion, and Metastasis , 2016, Biomolecules.

[2]  Wenpeng Zhang,et al.  Fully synthetic self-adjuvanting MUC1-fibroblast stimulating lipopeptide 1 conjugates as potential cancer vaccines. , 2016, Chemical communications.

[3]  Michael A. Hollingsworth,et al.  Functional Consequences of Differential O-glycosylation of MUC1, MUC4, and MUC16 (Downstream Effects on Signaling) , 2016, Biomolecules.

[4]  Md Kamal Hossain,et al.  Immunological Evaluation of Recent MUC1 Glycopeptide Cancer Vaccines , 2016, Vaccines.

[5]  S. Nishimura,et al.  Effects of the multiple O-glycosylation states on antibody recognition of the immunodominant motif in MUC1 extracellular tandem repeats , 2016 .

[6]  Y. Liu,et al.  Multi-component self-assembled anti-tumor nano-vaccines based on MUC1 glycopeptides. , 2016, Chemical communications.

[7]  Partha Karmakar,et al.  Synthesis of a Liposomal MUC1 Glycopeptide-Based Immunotherapeutic and Evaluation of the Effect of l-Rhamnose Targeting on Cellular Immune Responses. , 2016, Bioconjugate chemistry.

[8]  R. Payne,et al.  Synthetic self-adjuvanting glycopeptide cancer vaccines , 2015, Front. Chem..

[9]  V. Apostolopoulos,et al.  MUC1 (CD227): a multi-tasked molecule , 2015, Cellular and Molecular Life Sciences.

[10]  Yong-Xiang Chen,et al.  Glycopeptide Nanoconjugates Based on Multilayer Self-Assembly as an Antitumor Vaccine. , 2015, Bioconjugate chemistry.

[11]  M. Wolfert,et al.  Linear synthesis and immunological properties of a fully synthetic vaccine candidate containing a sialylated MUC1 glycopeptide. , 2015, Chemical communications.

[12]  S. Hartmann,et al.  Eine vollsynthetische Vier-Komponenten-Antitumor-Vakzine mit einem MUC1-Glycopeptid und drei verschiedenen T-Helferzell- Epitopen† , 2014 .

[13]  E. Schmitt,et al.  A fully synthetic four-component antitumor vaccine consisting of a mucin glycopeptide antigen combined with three different T-helper-cell epitopes. , 2014, Angewandte Chemie.

[14]  Scott N. Byrne,et al.  Synthesis and immunological evaluation of self-adjuvanting MUC1-macrophage activating lipopeptide 2 conjugate vaccine candidates. , 2014, Chemical communications.

[15]  A. M. Abdel-Aal,et al.  Immune and Anticancer Responses Elicited by Fully Synthetic Aberrantly Glycosylated MUC1 Tripartite Vaccines Modified by a TLR2 or TLR9 Agonist , 2014, Chembiochem : a European journal of chemical biology.

[16]  P. Mukherjee,et al.  MUC1: a multifaceted oncoprotein with a key role in cancer progression. , 2014, Trends in molecular medicine.

[17]  Guochao Liao,et al.  Synthesis and evaluation of monophosphoryl lipid A derivatives as fully synthetic self-adjuvanting glycoconjugate cancer vaccine carriers. , 2014, Organic & biomolecular chemistry.

[18]  Zhan-Yi Sun,et al.  Multivalente synthetische Glycopeptid‐Lipopeptid‐Antitumorvakzine: Auswirkung des Cluster‐Effekts auf das Abtöten von Tumorzellen , 2014 .

[19]  Yan‐Mei Li,et al.  Synthetic multivalent glycopeptide-lipopeptide antitumor vaccines: impact of the cluster effect on the killing of tumor cells. , 2014, Angewandte Chemie.

[20]  Yong Li,et al.  The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression , 2013, Cancer and Metastasis Reviews.

[21]  K. A. Wall,et al.  Synthesis and immunological evaluation of a MUC1 glycopeptide incorporated into l-rhamnose displaying liposomes. , 2013, Bioconjugate chemistry.

[22]  Yan‐Mei Li,et al.  Fully synthetic self-adjuvanting thioether-conjugated glycopeptide-lipopeptide antitumor vaccines for the induction of complement-dependent cytotoxicity against tumor cells. , 2013, Chemistry.

[23]  M. Grégoire,et al.  MUC1-Specific Cytotoxic T Lymphocytes in Cancer Therapy: Induction and Challenge , 2012, BioMed research international.

[24]  S. Buus,et al.  Cancer Associated Aberrant Protein O-Glycosylation Can Modify Antigen Processing and Immune Response , 2012, PloS one.

[25]  I. Toth,et al.  Design of fully synthetic, self-adjuvanting vaccine incorporating the tumor-associated carbohydrate Tn antigen and lipoamino acid-based Toll-like receptor 2 ligand. , 2012, Journal of medicinal chemistry.

[26]  M. Wolfert,et al.  Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine , 2011, Proceedings of the National Academy of Sciences.

[27]  Yan‐Mei Li,et al.  Towards a fully synthetic MUC1-based anticancer vaccine: efficient conjugation of glycopeptides with mono-, di-, and tetravalent lipopeptides using click chemistry. , 2011, Chemistry.

[28]  Brendan L Wilkinson,et al.  Self-adjuvanting multicomponent cancer vaccine candidates combining per-glycosylated MUC1 glycopeptides and the Toll-like receptor 2 agonist Pam3CysSer. , 2011, Angewandte Chemie.

[29]  Brendan L Wilkinson,et al.  Synthesis of MUC1-lipopeptide chimeras. , 2010, Chemical communications.

[30]  E. Schmitt,et al.  Fully synthetic vaccines consisting of tumor-associated MUC1 glycopeptides and a lipopeptide ligand of the Toll-like receptor 2. , 2010, Angewandte Chemie.

[31]  T. Becker,et al.  Vollsynthetische Vakzinen aus tumorassoziierten MUC1‐Glycopeptiden und einem Lipopeptid‐Liganden des Toll‐like Rezeptors 2 , 2010 .

[32]  J. Robertson,et al.  Malignancy-induced autoimmunity to MUC1: initial antibody characterization. , 2008, The journal of peptide research : official journal of the American Peptide Society.

[33]  L. BenMohamed,et al.  Towards a Self‐Adjuvanting Multivalent B and T cell Epitope Containing Synthetic Glycolipopeptide Cancer Vaccine , 2008, ChemMedChem.

[34]  R. Kennedy,et al.  Multiple roles for CD4+ T cells in anti‐tumor immune responses , 2008, Immunological reviews.

[35]  M. Wolfert,et al.  Robust immune responses elicited by a fully synthetic three-component vaccine. , 2007, Nature chemical biology.

[36]  F. Hanisch,et al.  O-Glycosylated Human MUC1 Repeats Are Processed In Vitro by Immunoproteasomes1 , 2007, The Journal of Immunology.

[37]  C. Griesinger,et al.  Synthesis and Structural Model of an α(2,6)‐Sialyl‐T Glycosylated MUC1 Eicosapeptide under Physiological Conditions , 2006 .

[38]  K. Knutson,et al.  Tumor antigen-specific T helper cells in cancer immunity and immunotherapy , 2005, Cancer Immunology, Immunotherapy.

[39]  Ellis L. Reinherz,et al.  Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles , 2004, Immunogenetics.

[40]  Hao Shen,et al.  Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory , 2003, Science.

[41]  S. Kuduk,et al.  Principles of mucin architecture: structural studies on synthetic glycopeptides bearing clustered mono-, di-, tri-, and hexasaccharide glycodomains. , 2002, Journal of the American Chemical Society.

[42]  M. Price,et al.  Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n‐acetylgalactosamine (GalNAc) peptides , 2000, International journal of cancer.

[43]  P. Ciborowski,et al.  Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4+ T cells. , 1998, Cancer research.

[44]  M. Hollingsworth,et al.  CD4+ lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice. , 1998, Journal of immunology.

[45]  M. Hollingsworth,et al.  Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. , 1998, Cancer research.

[46]  V. Apostolopoulos,et al.  Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. , 1997, Journal of immunology.

[47]  V. Apostolopoulos,et al.  MUC1 peptide epitopes associated with five different H‐2 class I molecules , 1997, European journal of immunology.